Alterations in DNA damage response and repair genes as potential marker of clinical benefit from PD-1/PD-L1 blockade in advanced urothelial cancers.
Journal of Clinical Oncology.
Times cited: 2
- Drug development for noncastrate prostate cancer in a changed therapeutic landscape. Nature Reviews Clinical Oncology. 2018 Review GET IT
- Synthetic lethality: Achilles heel in select patient subpopulations. 2017 Chapter GET IT